Recent Updates
Recently added Catalysts
TMDX Positive Sentiment

TransMedics to Present at Upcoming September Investor Conferences

Key Takeaway: TransMedics Group, Inc. will participate in two investor conferences in September 2026. The management team is scheduled for a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference and the Baird 2026 Global Healthcare Conference. These events highlight the company's commitment to advancing organ transplant therapy.
Price reaction · baseline $84.87 (2026-08-31 close) · hit after-hours · clean, no other TMDX news in the window
day 0 close · peak
-3.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • TransMedics is participating in two significant investor conferences.
  • The company is a leader in organ transplant technology.
  • Management's engagement in investor discussions indicates confidence in their growth.

Full Press Release Details

ANDOVER, Mass., Aug. 31, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences. TransMedics management is scheduled to participate in a fireside chat at the Morgan Stanley 24 th Annual Global Healthcare Conference in New York on Monday, September 14, 2026, at 3:20 p.m. EST and at the Baird 2026 Global Healthcare Conference in New York on Tuesday, September 15, 2026, at 9:40 a.m. EST.

Event: Morgan Stanley 24th Annual Global Healthcare Conference Date: Monday, September 14, 2026 Time: 3:20 p.m. EST

Event: Baird 2026 Global Healthcare Conference Date: Tuesday, September 15, 2026 Time: 9:40 a.m. EST

A live and archived webcast of the fireside chat will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/. The Company's standard investor presentation is also available through this link.
About TransMedics Group, Inc. TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.

Investor Contact: Brian Johnston Hannah Jeffrey 332-895-3222 [email protected]

Frequently Asked Questions

When is TransMedics participating in investor conferences?

TransMedics will participate in conferences on September 14 and 15, 2026.

Where can I watch the TransMedics fireside chat?

The fireside chat will be available on the TransMedics Investors section of their website.

What is TransMedics known for?

TransMedics is a leader in portable extracorporeal warm perfusion for organ transplantation.

What technology does TransMedics develop?

TransMedics develops technologies to preserve organ quality and assess viability for transplants.

Last updated: Aug 31, 2026